ALL-MED - Specjalistyczna Opieka Medyczna - Medyczny Instytut Badawczy

The research team at ALL-MED - Specjalistyczna Opieka Medyczna - Medyczny Instytut Badawczy is focusing on innovative treatments for perennial allergic rhinitis. Current studies aim to assess how a targeted antibody can reduce nasal congestion and other persistent symptoms, offering a potential new option for patients who have limited relief from existing therapies.

• Evaluation of nasal symptom relief
• Comparison with placebo outcomes
• Impact on quality of life measures

These investigations contribute to the broader effort to improve management of chronic upper airway inflammation and provide clearer guidance for clinicians treating this condition.

In the respiratory domain, investigators are examining the long‑term safety of Depemokimab (GSK3511294) for individuals with severe asthma featuring an eosinophilic phenotype. The open‑label extension study monitors participants over a year to ensure that the biologic remains well‑tolerated while delivering sustained disease control alongside standard asthma therapy.

• Long‑term safety monitoring
• Assessment of eosinophil‑driven inflammation
• Integration with existing asthma treatments

Findings from this work aim to expand therapeutic options for patients whose asthma is difficult to manage, potentially reducing exacerbations and improving overall respiratory health.